Inclusion Criteria:

          -  Newly diagnosed AJCC7 clinical stage II or III breast cancer with complete surgical
             excision of the breast cancer after neoadjuvant chemotherapy as the treatment goal.

          -  Patients with PR+ tumors are allowed.

          -  HER2 negative by FISH or IHC staining 0 or 1+.

          -  ER less than Allred score of 3 or less than 1% positive staining cells in the invasive
             component of the tumor

          -  Tumor size at least 2cm in one dimension by clinical or radiographic exam (WHO
             criteria). Patients with palpable lymph nodes may be enrolled regardless of tumor
             size.

          -  At least 18 years of age.

          -  ECOG performance status ≤ 2

          -  Normal bone marrow and organ function as defined below:

               -  Leukocytes ≥ 3,000/mcL

               -  Absolute neutrophil count ≥ 1,500/mcl

               -  Platelets ≥ 100,000/mcl

               -  Serum bilirubin within (or under ) normal limits (OR total bilirubin ≤ 3.0 x IULN
                  with direct bilirubin within normal range in patients with well documented
                  Gilbert Syndrome)

               -  AST(SGOT)/ALT(SGPT) within (or under ) normal limits

               -  Creatinine clearance ≥ 60 mL/min/1.73 m2

          -  Patients may be pre- or post-menopausal. Women of childbearing potential must agree to
             use adequate contraception (hormonal or barrier method of birth control, abstinence)
             prior to study entry and for the duration of study participation. Should a woman
             become pregnant or suspect she is pregnant while participating in this study, she must
             inform her treating physician immediately.

          -  Ability to understand and willingness to sign an IRB approved written informed consent
             document (or that of legally authorized representative, if applicable).

          -  Able to tolerate PET/MRI with intravenous contrast administration and must complete
             the applicable MRI screening evaluation form

        Exclusion Criteria:

          -  Prior systemic therapy for the indexed breast cancer.

          -  A history of other malignancy ≤ 5 years previous with the exception of basal cell or
             squamous cell carcinoma of the skin which were treated with local resection only or
             carcinoma in situ of the cervix.

          -  Patients with bilateral or inflammatory breast cancer.

          -  Currently receiving any other investigational agents.

          -  A history of allergic reactions attributed to compounds of similar chemical or
             biologic composition to docetaxel or carboplatin.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Pregnant and/or breastfeeding. Patient must have a negative serum pregnancy test
             within 7 days of study entry if premenopausal.

          -  Known HIV-positivity.

          -  Sentinel lymph node biopsy

          -  Renal insufficiency (glomerular filtration rate (GFR) < 30 mL/min/1.73 m2) measured
             within the past 60 days which precludes safe administration of the contrast agent

          -  On dialysis

          -  Prior allergic reaction to gadolinium-based MR contrast agents